Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minimum inhibitory concentration distributions for Mycobacterium avium complex—towards evidence-based susceptibility breakpoints

7 Jan 2017

Abstract excerpt

BACKGROUND: Patients with clinical infections caused by the Mycobacterium avium complex (MAC) are treated for at least 1 year following sputum conversion with a regimen that suffers from a suboptimal cure rate. The correlation between clinical outcome and drug susceptibility testing breakpoints other than for the macrolides is regarded to be poor. A systematic evaluation of clinical breakpoints for MAC has not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Infectious Diseases and Tuberculosis
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28069470
DOI: 10.1016/j.ijid.2016.12.027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minimum inhibitory concentration distributions for Mycobacterium avium complex—towards evidence-based susceptibility breakpointsPMID 28069470Read ↗

Variability of Mycobacterium avium Complex Isolates Drug Susceptibility Testing by Broth MicrodilutionSemantic proximity Read ↗

<i>In Vitro</i> Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated IsolatesSemantic proximity Read ↗

Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.Semantic proximity Read ↗

Drug Susceptibility Testing of Nontuberculous MycobacteriaSemantic proximity Read ↗

Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates.Semantic proximity Read ↗

Comparative analysis of phenotypic and genotypic antibiotic susceptibility patterns in Mycobacterium avium complex.Semantic proximity Read ↗

Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed rpoB Mutations and Discordant Susceptibility Phenotypes.Semantic proximity Read ↗

European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteriaSemantic proximity Read ↗

Divergent Minimum Inhibitory Concentrations of Clarithromycin and Azithromycin Against Clinical Isolates of <i>Mycobacterium abscessus</i> ComplexSemantic proximity Read ↗

Critical Assessment of Issues Applicable to Development of Antimicrobial Susceptibility Testing BreakpointsSemantic proximity Read ↗

Phenotypic amikacin resistance may not indicate poor response to amikacin in Mycobacterium avium complex pulmonary disease.Semantic proximity Read ↗

Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.